SU 11274
SU 11274 Basic information
- Product Name:
- SU 11274
- Synonyms:
-
- (3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide
- (3Z)-N-(3-Chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo-1H-indole-5-sulfonamide
- Met Kinase Inhibitor - CAS 658084-23-2 - Calbiochem
- SU-11274;PKI-SU11274;SU 11274
- PKI-SU11274
- N-(3-Chlorophenyl)-N-methyl-3-[[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
- N-(3-Chlorophenyl)-N-methyl-3-[[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide SU11274
- SU 11274, >=98%
- CAS:
- 658084-23-2
- MF:
- C28H30ClN5O4S
- MW:
- 568.09
- Product Categories:
-
- Inhibitors
- Mol File:
- 658084-23-2.mol
SU 11274 Chemical Properties
- Density
- 1.401±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- DMSO: 10 mg/mL at 60 °C
- pka
- 11.62±0.20(Predicted)
- form
- powder
- color
- orange
- InChIKey
- FPYJSJDOHRDAMT-KQWNVCNZSA-N
SU 11274 Usage And Synthesis
Description
MET is a proto-
Uses
SU 11274 is a competitive inhibitor of Met kinase activity.
Definition
ChEBI: 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- is a sulfonamide.
Biochem/physiol Actions
SU 11274 is a class I c-Met inhibitor that competes with ATP to bind to the activation loop of c-Met.1 Inhibition of c-Met by SU 11274 is effective in improving the clinical outcome in non-small cell lung cancer cell lines.2
References
[1] wang x1, le p, liang c, chan j, kiewlich d, miller t, harris d, sun l, rice a, vasile s, blake ra, howlett ar, patel n, mcmahon g, lipson ke. potent and selective inhibitors of the met [hepatocyte growth factor/scatter factor (hgf/sf) receptor] tyrosine kinase block hgf/sf-induced tumor cell growth and invasion. mol cancer ther. 2003 nov;2(11):1085-92.
[2] leiser d1, pochon b1, blank-liss w1, francica p1, glück aa1, aebersold dm1, zimmer y1, medová m2. targeting of the met receptor tyrosine kinase by small molecule inhibitors leads to met accumulation by impairing the receptor downregulation. febs lett. 2014 mar 3;588(5):653-8.
SU 11274Supplier
- Tel
- sales@boylechem.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- +86 (0) 571 85 58 67 18
- sales@capotchem.com
- Tel
- 86-0571-85151182
- Tel
- +86 (531) 88811783
- sales@trio-pharmatech.com (International market)
SU 11274(658084-23-2)Related Product Information
- SUN11602
- SU 4942
- SU 5205
- (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide
- SU 4312
- FORMANILIDE
- Acetanilide
- 5-CHLORO-3-[(3,5-DIMETHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE
- SU5402
- N-Desethyl Sunitinib
- PHA-665752
- 1,9-Pyrazoloanthrone
- Dasatinib
- Crizotinib
- Olaparib
- BEZ235 (NVP-BEZ235, Dactolisib)
- 3-(4-ISOPROPYLBENZYLIDENYL)INDOLIN-2-ONE
- SU 5214